MedImmune Moves To Block Ethyol Generic Challenger
This article was originally published in The Pink Sheet Daily
Sun’s labeling would put patients at risk, MedImmune claims.
You may also be interested in...
Deal for development of two candidates could be worth up to half a billion dollars.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4